


# Gabather

---

SHAREHOLDER'S MEETING PRESENTATION • JUNE 4, 2020

# The GABA<sub>A</sub> receptor as a drug target

---



- GABA – the main inhibitory neurotransmitter system in the brain
- One target addressing several potential indications
- Gabather's lead drug candidate, GT-002, is a highly potent and selective GABA<sub>A</sub> receptor modulator with a unique mechanism of action

Strong preclinical data for pro-cognitive, anti-depressant and anti-psychotic effects

# A brief update on Gabather's development

---

- Novel oral formulation in capsules – patent application submitted
- Final data from SAD study of GT-002 reported:
  - Good orally bioavailability and pharmacokinetic properties in humans
  - Safe and well tolerated in humans
- Multiple ascending dose (MAD) study starting summer 2020
- Potential primary indication/patient group – Mild Cognitive Impairment in Major Depressive Disorders
- In-house research program ongoing – work on second patent group
- Company consolidation to the Södertälje site

# GT-002: A GABA<sub>A</sub> receptor modulator with large potential

---

## Gabather's drug candidate GT-002

- A novel pro-cognitive agent with social interaction enhancing properties and antipsychotic profile suggesting multiple indication potential


## Market potential

- June 2018: Sage Therapeutics completed a \$575M phase 2 licensing deal with the GABA<sub>A</sub> receptor modulator, SAGE-217, for the treatment of postpartum depression (PPD)
- January 2019: SAGE announced the successful completion of phase 3 clinical trials with SAGE-217 in PPD
- Clinical trial in multiple indications ongoing – top line data in 2021

# The Gabather road map

---

- Build a portfolio of CNS projects in different stages of development, all targeting the GABA<sub>A</sub> receptor
- Secure licensing deals with larger companies at well-defined points-in-time



## Key objectives next 12 months

---

- Completion of multiple ascending dose (MAD) study
- Completion of target engagement study
- Initiation of proof of concept (POC) studies in patients
- New clinical candidate from research program